

Open Peer Review on Qeios

Ruxolitinib Phosphate

National Cancer Institute

Source

National Cancer Institute. <u>Ruxolitinib Phosphate</u>. NCI Thesaurus. Code C97937.

The phosphate salt form of ruxolitinib, an orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.

Qeios ID: MBLFMS · https://doi.org/10.32388/MBLFMS